Grand Pharmaceutical Group (HKG:0512) was recently granted a drug registration certificate for its fluticasone propionate nasal spray by China's National Medical Products Administration, a Monday Hong Kong bourse filing said.
The nasal spray was developed by the pharmaceutical company for the treatment of allergic rhinitis.